Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 3/20 | 0.52 |
| ▸ | RAB9A | P51151 | 3/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | RECQL | P46063 | 1/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.44 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578149 | 0.91 | GRM5 (0.58) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL1579128 | 0.86 | GRM5 (0.54) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL1578303 | 0.85 | FAAH (0.62) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL1578460 | 0.84 | GRM5 (0.54) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL2278707 | 0.84 | ALDH1A1 (0.63) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL1578628 | 0.83 | GRM5 (0.71) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL1578601 | 0.83 | GRM5 (0.54) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL2280375 | 0.83 | GRM5 (0.52) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL2223415 | 0.83 | ALDH1A1 (0.54) | GRM5RAB9AKDM4EMAPTAGTR1 | |
| SCHEMBL2638308 | 0.83 | PABPC1 (0.65) | RAB9AKDM4EMAPTAGTR1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8716284-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2014-05-06 | — | — | US | disclosed |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2013-07-18 | — | — | US | disclosed |
| US-8389519-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2013-03-05 | — | — | US | disclosed |
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2012-10-25 | — | — | US | disclosed |
| US-8198275-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S (DK) | 2012-06-12 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2011-07-21 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| US-7947680-B2 | Adamantyl diamide derivatives and uses of same | H. LUNDBECK A/S | 2011-05-24 | — | — | US | disclosed |
| EP-2310356-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. Lundbeck A/S (DK) | 2011-04-20 | — | — | EP | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | H. LUNDBECK A/S (DK) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120270873-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3873/4885RAB9A 333/4885KDM4E 2855/4885 |
| US-20130184277-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3895/4885RAB9A 356/4885KDM4E 2889/4885 |
| US-20100022546-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, ADM2, PDE3B | GRM5 4054/4885RAB9A 314/4885KDM4E 2749/4885 |
| US-20110178086-A1 | ADAMANTYL DIAMIDE DERIVATIVES AND USES OF SAME | QDPR, PDE3B, ADM2 | GRM5 3873/4885RAB9A 333/4885KDM4E 2855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.